Afuco™ Platform
1. Introduction Treatment of cancer with therapeutic antibodies Recombinant therapeutic antibodies represent a successful new class of drugs developed over the past two decades. Researchers are able to design antibodies that specifically target a certain antigen, such as the one found on cancer cells before then multiplying said antibody in the lab. The result are monoclonal antibodies that are used to treat many diseases, including some types of cancer. One mechanism of action of antibody-based immunotherapy is the activation of immune effector cells to mediate antibody-dependent cellmediated cytotoxicity (ADCC). Thus, ADCC enhancement is important to push the efficacy of cancer antibodies as the artificially decreased fucose content that leads to ADCC also results in an elevated killing activity against tumorigenic and infected cells, making them more powerful and efficient. So it is hardly surprising that the popularity of ADCC enhanced antibodies to be utilized in the development of next-generation therapeutic antibodies is constantly growing. Creative Biolabs provides a comprehensive list of therapeutic antibodies with enhanced antibody-dependent cellular cytotoxicity to accelerate your research process.
Fig.1 Moa of ADCC. The benefits of ADCC enhanced antibodies ADCC enhanced antibodies, also known as afucosylated antibodies, are artificially cultivated monoclonal antibodies engineered to exhibit a decreased fucose content that in turn leads to higher ADCC. ADCC forms part of the humoral immune response to limit and contain infection and has recently been identified as one of the critical mechanisms underlying the clinical efficacy of therapeutic antibodies, especially anticancer antibodies. Therapeutic antibodies fully lacking the core fucose of the Fc oligosaccharides have been found to exhibit much higher ADCC in humans than their fucosylated counterparts. But why are ADCC enhanced antibodies seeing such a steady rise in popularity? Well, they exhibit a number of significant benefits, the three major ones being: enhanced ADCC activity improved FcγIIIa binding properties – quick and easy cultivation with a profitable yield Thanks to these beneficial properties, they can be used in a number of medications and treatments targeting autoimmune diseases, cancer and viral diseases such as COVID-19. In the particular case of ADCC enhanced antibodies, those binding properties are further amplified, resulting in an elevated killing activity against tumorigenic and infected cells. Afuco™ platform for ADCC enhancement from Creative Biolabs The constantly growing demand is just one of the reasons why antibody production and design plays a crucial role in today’s life-science industry, be it to increase activity as well as functionality, reduce immunogenicity or extend the half-life. The scientists at Creative Biolabs are specializing in afucosylated antibodies for ADCC enhancement. One of the most recent additions to the 1-631-357-2254 | info@creative-biolabs.com | CREATIVE BIOLABS INC
3